EHR companies asked to incorporate information about oral antivirals
As the nation’s death toll from COVID-19 inches towards one million, the Biden administration is intensifying efforts to inform clinicians and ordinary Americans about treatments for the disease, and to make testing and treatment more widely available.
In a White House fact sheet released Tuesday, the administration outlined the latest steps the government is taking to distribute medications for treating COVID and inform people about their availability. These include:
Responding to the White House fact sheet, a spokesperson for the Electronic Health Record Assocation (EHRA) said in a statement, “Just as we have for clinical alerts in general, EHRA members have worked closely with their clients, the CDC, and other agencies throughout the pandemic to ensure that, as new COVID-19 vaccines and treatments become available, clinicians are provided with the most appropriate alerts and reminders in the right context within the EHR. The EHRA continues to work with key stakeholders to increase awareness and best practices as we work toward reducing the impact of the pandemic.”
This article was originally published by sister publication Medical Economics.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.